Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Incorporated    LGND

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Left's Citron hedge fund posts 43% gain in first year

share with twitter share with LinkedIn share with facebook
share via e-mail
01/06/2020 | 07:09pm EDT
Andrew Left, the founder of Citron Research, speaks during the Reuters Global Investment 2019 Outlook Summit, in New York

Andrew Left, who has long targeted companies that he thinks are over-valued through his work at Citron Research, told investors on Monday that his new hedge fund returned 43% after fees in 2019, its first year in business.

Left also made a prediction that home furnishing company RH, one of his winners last year, may make a tempting takeover target for someone.

"In 2019, our first full year of operation, Citron Capital, LP ("Fund") generated a gross return of 56.4% and net return of 43.3%," Left wrote in the letter seen by Reuters.

While the fund bet that certain stocks would climb, Left also bet that certain ones would drop, writing "the Fund's average exposure during 2019 was 75.8% long and 80.3% short."

Left said that winners on the long side included Bausch Health, RH, and Snap and on the short side included Ligand Pharmaceuticals, Jumia Technologies, and Grand Canyon Education.

After investing only his own wealth for roughly two decades,Left in 2018 began laying the groundwork for Citron Capital, his hedge fund. By raising outside capital, Left has more firepower to go after some of the biggest U.S. companies.

Citron has not disclosed the size of its hedge fund.

For this year, Left said RH, whose stock price closed at $212.77 on Monday, may be bought. "We believe the company has matured to a point that we might see it acquired in 2020."

He also said he is sticking by his bet that shares in Peloton Interactive, whose stock closed at $29.75 on Monday, will fall. "Citron put a one-year price target of $5 and we stand by it as $5 makes this still a $1.5 billion company."

Neither RH nor Peloton responded immediately to emails seeking comment.

Left also gave investors lessons that he learned last year; reminding himself and others to stay away from what he calls "big story 'cult stock'" companies and sticking with what he does best: exposing fraud.

He also said that this year will be a year of growth and that he is looking to expand beyond his home base in Los Angeles.

(Reporting by Svea Herbst-Bayliss with additional reporting by Lawrence Delevingne; editing by Richard Pullin)

By Svea Herbst-Bayliss

Stocks mentioned in the article
ChangeLast1st jan.
BAUSCH HEALTH COMPANIES INC. 14.86% 18.01 Delayed Quote.-38.10%
GRAND CANYON EDUCATION, INC. 1.10% 76.3 Delayed Quote.-20.35%
JUMIA TECHNOLOGIES AG -6.25% 2.85 Delayed Quote.-57.65%
LIGAND PHARMACEUTICALS INCORPORATED 4.11% 86.42 Delayed Quote.-17.13%
MTN GROUP LIMITED -7.65% 47.45 End-of-day quote.-10.45%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LIGAND PHARMACEUTICALS INC
04/06LIGAND PHARMACEUTICALS INCORPORATED : Provides a Corporate Update and Announces ..
BU
04/02LIGAND PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
AQ
04/02LIGAND PHARMACEUTICALS INCORPORATED : Completes Acquisition of Icagen Core Asset..
BU
03/10LIGAND PHARMACEUTICALS INCORPORATED : Presentation at the Barclays Global Health..
BU
03/02LIGAND PHARMACEUTICALS INCORPORATED : Management to Present at Two Investor Conf..
BU
02/27LIGAND PHARMACEUTICALS INCORPORATED : INC Management's Discussion and Analysis o..
AQ
02/27LIGAND PHARMACEUTICALS INCORPORATED : Raises 2020 Financial Guidance Due to High..
BU
02/11LIGAND PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other E..
AQ
02/11LIGAND PHARMACEUTICALS INCORPORATED : Agrees to Acquire Core Assets, Partnered P..
BU
02/06LIGAND : 4Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2020 131 M
EBIT 2020 27,3 M
Net income 2020 4,66 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 102x
P/E ratio 2021 35,9x
Capi. / Sales2020 10,9x
Capi. / Sales2021 9,80x
Capitalization 1 426 M
Chart LIGAND PHARMACEUTICALS INCORPORATED
Duration : Period :
Ligand Pharmaceuticals Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LIGAND PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 158,71  $
Last Close Price 86,42  $
Spread / Highest target 165%
Spread / Average Target 83,7%
Spread / Lowest Target -38,7%
EPS Revisions
Managers
NameTitle
John L. Higgins Chief Executive Officer & Director
Matthew William Foehr President & Chief Operating Officer
John W. Kozarich Chairman
Matthew Edward Korenberg Chief Financial Officer & EVP-Finance
Eric Vajda Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
LIGAND PHARMACEUTICALS INCORPORATED-17.13%1 426
LONZA GROUP14.61%30 757
IQVIA HOLDINGS INC.-15.96%24 655
CELLTRION, INC.-0.47%22 757
SEATTLE GENETICS, INC.5.30%20 657
INCYTE CORPORATION0.49%19 022